SlideShare a Scribd company logo
1 of 4
Val	
  in	
  Crs
MAT MTH Val	
  (Cr) MS% GR% Val	
  (Cr) MS% GR% CORPORATE
80565 100.00 9.1 7738 100.00 18.8 IPM
1 1 5030 6.24 5.8 467 6.03 16.7 Abbott	
  +	
  Abbott	
  HC	
  +	
  Novo
2 3 4343 5.39 15.0 378 4.89 8.9 Sun	
  Pharma
3 2 4038 5.01 10.3 427 5.51 38.4 Cipla
4 4 3480 4.32 8.0 312 4.03 12.0 Zydus	
  +	
  Biochem
5 7 2908 3.61 4.9 273 3.53 15.8 Ranbaxy
6 5 2899 3.60 10.2 305 3.95 30.9 Mankind
7 6 2887 3.58 13.8 290 3.75 19.1 Alkem	
  +	
  Cachet	
  +	
  Indchemie
8 8 2729 3.39 -­‐11.1 264 3.41 14.9 Glaxo
9 9 2710 3.36 12.8 259 3.35 19.7 Lupin
10 12 2348 2.91 6.3 229 2.96 23.9 Pfizer
11 10 2279 2.83 21.4 244 3.15 44.2 Macleods
12 14 2193 2.72 11.1 191 2.47 4.9 Emcure	
  +	
  Zuventus
13 13 2098 2.60 15.3 195 2.51 18.8 Intas
14 11 2023 2.51 19.9 230 2.98 39.7 Aristo
15 16 1984 2.46 -­‐0.5 180 2.32 13.2 Sanofi	
  India
16 18 1779 2.21 5.4 167 2.15 18.4 Torrent
17 15 1754 2.18 16.6 185 2.39 27.0 Glenmark
18 17 1719 2.13 9.4 167 2.15 17.5 Dr.	
  Reddys
19 20 1616 2.01 12.0 143 1.85 4.6 Micro	
  +	
  Bal
20 19 1470 1.82 24.7 152 1.96 22.1 Ipca
21 21 1466 1.82 10.0 128 1.66 7.6 USV
22 23 1145 1.42 -­‐1.0 105 1.36 13.4 Novartis
23 22 1103 1.37 12.8 117 1.51 30.6 Alembic
24 25 993 1.23 6.1 84 1.09 7.6 Wockhardt
25 24 843 1.05 6.8 90 1.16 24.0 FDC
26 26 815 1.01 10.7 77 0.99 13.0 Unichem
27 27 794 0.99 12.9 70 0.90 10.0 MSD	
  +	
  Fulford	
  +	
  Organon
28 29 687 0.85 16.0 60 0.78 9.6 Cadila
29 28 633 0.79 13.4 68 0.88 34.4 Indoco	
  Remedies
30 30 590 0.73 12.5 56 0.73 13.1 Franco
31 31 581 0.72 18.1 49 0.64 12.2 Eris
32 33 491 0.61 8.3 48 0.62 17.2 Himalaya
33 32 483 0.60 10.4 48 0.62 21.6 Merck
34 34 441 0.55 6.3 47 0.60 27.1 Blue	
  Cross
35 36 441 0.55 16.6 45 0.58 41.5 JB	
  Chemicals
36 38 398 0.49 -­‐6.4 43 0.55 49.9 Bharat	
  Serums
37 47 396 0.49 -­‐0.2 30 0.38 -­‐18.0 Astrazeneca
38 39 391 0.49 22.6 38 0.50 23.9 Meyer	
  Organics
39 40 385 0.48 2.4 37 0.48 12.8 Raptakos,	
  Brett
40 35 384 0.48 50.9 46 0.60 92.5 Akumentis
41 37 373 0.46 16.6 44 0.57 48.2 Hetero
42 43 372 0.46 9.8 35 0.45 12.1 Wallace	
  +	
  Indi	
  Pharma
43 42 353 0.44 16.1 36 0.47 26.9 Medley
44 46 342 0.42 10.8 31 0.40 18.8 Janssen
45 44 338 0.42 2.6 33 0.43 13.6 Win-­‐Medicare
46 45 332 0.41 10.7 32 0.41 14.4 Fourrts
47 49 315 0.39 38.4 28 0.37 35.9 Ajanta
48 48 310 0.39 41.7 29 0.38 22.1 Biocon
With	
  Bonus	
  Units	
  at	
  Full	
  Value
Rank MAT	
  Sep	
  -­‐14 Sep-­‐14
49 41 309 0.38 33.0 36 0.47 62.2 Apex	
  Lab
50 51 301 0.37 5.6 27 0.35 -­‐2.3 Albert	
  David
MAT MTH Val	
  (Cr) MS% GR% Val	
  (Cr) MS% GR%
77530 100.00 9.2 7421 100.00 18.6
1 1 4934 6.36 5.8 457 6.15 16.9
2 3 4241 5.47 14.2 368 4.95 8.1
3 2 3799 4.90 12.6 399 5.38 38.7
4 4 3254 4.20 7.7 292 3.94 11.1
5 7 2799 3.61 5.2 262 3.53 15.8
9 6 2475 3.19 12.1 265 3.57 33.7
7 5 2692 3.47 14.5 270 3.64 20.0
6 8 2704 3.49 -­‐10.1 262 3.53 15.5
8 9 2654 3.42 13.0 254 3.42 20.3
10 11 2298 2.96 6.7 224 3.02 23.9
11 10 2135 2.75 21.2 226 3.05 43.9
12 14 2127 2.74 11.4 184 2.48 4.7
13 13 2070 2.67 15.6 192 2.59 19.0
15 12 1772 2.29 17.4 198 2.67 36.1
14 16 1944 2.51 -­‐0.7 175 2.36 12.5
16 17 1744 2.25 5.7 163 2.20 18.3
17 15 1701 2.19 16.2 179 2.41 26.4
18 18 1682 2.17 8.6 162 2.18 16.7
19 20 1546 1.99 12.5 136 1.83 4.1
21 19 1404 1.81 25.0 145 1.95 22.5
20 21 1460 1.88 10.1 128 1.72 7.8
22 23 1108 1.43 0.0 102 1.38 14.3
23 22 1072 1.38 13.5 114 1.53 31.3
24 25 974 1.26 6.2 83 1.11 7.4
25 24 819 1.06 6.7 87 1.18 24.0
26 26 797 1.03 10.3 75 1.01 12.8
27 27 783 1.01 12.6 68 0.92 9.5
28 29 665 0.86 16.1 58 0.78 9.2
29 28 593 0.76 13.4 63 0.85 33.7
31 30 569 0.73 11.9 54 0.73 12.6
30 31 578 0.74 17.9 49 0.66 12.4
32 32 489 0.63 8.0 48 0.64 17.0
33 33 471 0.61 9.4 46 0.63 21.1
35 36 405 0.52 7.1 42 0.57 26.5
34 35 424 0.55 16.7 43 0.59 42.4
37 37 391 0.50 -­‐6.8 42 0.57 49.5
36 47 392 0.51 -­‐0.6 29 0.40 -­‐17.7
39 39 379 0.49 22.4 37 0.50 23.4
38 40 379 0.49 2.2 37 0.50 12.9
40 34 377 0.49 52.4 46 0.61 94.0
43 38 339 0.44 16.7 40 0.54 46.7
41 43 353 0.46 17.4 34 0.46 22.3
44 42 335 0.43 16.4 34 0.46 26.8
42 45 341 0.44 10.8 31 0.42 18.8
45 44 333 0.43 1.2 33 0.44 13.1
46 46 316 0.41 9.7 30 0.40 12.8
47 49 313 0.40 38.2 28 0.38 35.8
48 48 310 0.40 41.7 29 0.39 22.1
Without	
  Bonus	
  Units
Rank MAT	
  Sep	
  -­‐14 Sep-­‐14
49 41 300 0.39 33.1 35 0.48 64.3
50 51 295 0.38 5.4 27 0.36 -­‐2.8

More Related Content

What's hot

Pharmaceutical Marketing Complete Notes
Pharmaceutical Marketing Complete NotesPharmaceutical Marketing Complete Notes
Pharmaceutical Marketing Complete NotesGhulam Murtaza Hamad
 
Microencapsulation
MicroencapsulationMicroencapsulation
MicroencapsulationSagar Savale
 
OTC drugs (Amended rules) Drug and Cosmetic Act, 1940 & Rules,1945
OTC drugs (Amended rules) Drug and Cosmetic Act, 1940 & Rules,1945OTC drugs (Amended rules) Drug and Cosmetic Act, 1940 & Rules,1945
OTC drugs (Amended rules) Drug and Cosmetic Act, 1940 & Rules,1945Yamini Shah
 
Sinecod product training_final(1)
Sinecod product training_final(1)Sinecod product training_final(1)
Sinecod product training_final(1)rssergei9
 
Transdermal drug delivery system
Transdermal drug delivery systemTransdermal drug delivery system
Transdermal drug delivery systemGauravchaudhary199
 
CHARACTERIZATION OF GRANULES.
CHARACTERIZATION OF GRANULES.CHARACTERIZATION OF GRANULES.
CHARACTERIZATION OF GRANULES.vinayak phakatkar
 
ORAL DISINTEGRATION / DISPERSIBLE TABLET
ORAL DISINTEGRATION  / DISPERSIBLE TABLETORAL DISINTEGRATION  / DISPERSIBLE TABLET
ORAL DISINTEGRATION / DISPERSIBLE TABLETSatya Shukla
 
Ims molecule share (market size) 2013 bangladesh pharmaceutical industries
Ims molecule share (market size) 2013 bangladesh pharmaceutical industriesIms molecule share (market size) 2013 bangladesh pharmaceutical industries
Ims molecule share (market size) 2013 bangladesh pharmaceutical industriesMohammad Masum Chowdhury
 
Pulsatile drug delivery
Pulsatile drug deliveryPulsatile drug delivery
Pulsatile drug deliverypaudelmanoj
 
Dietary Supplements, a Glance at Global Trends
Dietary Supplements, a Glance at Global TrendsDietary Supplements, a Glance at Global Trends
Dietary Supplements, a Glance at Global TrendsFarhad Zargari
 
Key Stakeholders and the effect of their actions on the Financial Sustainabil...
Key Stakeholders and the effect of their actions on the Financial Sustainabil...Key Stakeholders and the effect of their actions on the Financial Sustainabil...
Key Stakeholders and the effect of their actions on the Financial Sustainabil...simonho8
 
Dry Powder Inhalers (DPIs) - At a glance
Dry Powder Inhalers (DPIs) -  At a glanceDry Powder Inhalers (DPIs) -  At a glance
Dry Powder Inhalers (DPIs) - At a glanceDr. Girish S Sonar
 
Mergers and Acquisitions in Indian Pharma Industry
Mergers and Acquisitions in Indian Pharma IndustryMergers and Acquisitions in Indian Pharma Industry
Mergers and Acquisitions in Indian Pharma IndustryNaveen Kumar
 

What's hot (20)

Microspheres
MicrospheresMicrospheres
Microspheres
 
Pharmaceutical Marketing Complete Notes
Pharmaceutical Marketing Complete NotesPharmaceutical Marketing Complete Notes
Pharmaceutical Marketing Complete Notes
 
Microencapsulation
MicroencapsulationMicroencapsulation
Microencapsulation
 
OTC drugs (Amended rules) Drug and Cosmetic Act, 1940 & Rules,1945
OTC drugs (Amended rules) Drug and Cosmetic Act, 1940 & Rules,1945OTC drugs (Amended rules) Drug and Cosmetic Act, 1940 & Rules,1945
OTC drugs (Amended rules) Drug and Cosmetic Act, 1940 & Rules,1945
 
Sinecod product training_final(1)
Sinecod product training_final(1)Sinecod product training_final(1)
Sinecod product training_final(1)
 
Transdermal drug delivery system
Transdermal drug delivery systemTransdermal drug delivery system
Transdermal drug delivery system
 
CHARACTERIZATION OF GRANULES.
CHARACTERIZATION OF GRANULES.CHARACTERIZATION OF GRANULES.
CHARACTERIZATION OF GRANULES.
 
ORAL DISINTEGRATION / DISPERSIBLE TABLET
ORAL DISINTEGRATION  / DISPERSIBLE TABLETORAL DISINTEGRATION  / DISPERSIBLE TABLET
ORAL DISINTEGRATION / DISPERSIBLE TABLET
 
Moxikind CV- Brand Plan
Moxikind CV- Brand PlanMoxikind CV- Brand Plan
Moxikind CV- Brand Plan
 
Ims molecule share (market size) 2013 bangladesh pharmaceutical industries
Ims molecule share (market size) 2013 bangladesh pharmaceutical industriesIms molecule share (market size) 2013 bangladesh pharmaceutical industries
Ims molecule share (market size) 2013 bangladesh pharmaceutical industries
 
Consumer behavior in Pharmacies
Consumer behavior in PharmaciesConsumer behavior in Pharmacies
Consumer behavior in Pharmacies
 
Clinical research protocol
Clinical research protocolClinical research protocol
Clinical research protocol
 
Losart (Losar
Losart (LosarLosart (Losar
Losart (Losar
 
Pulsatile drug delivery
Pulsatile drug deliveryPulsatile drug delivery
Pulsatile drug delivery
 
Mucoadhesive dds
Mucoadhesive ddsMucoadhesive dds
Mucoadhesive dds
 
TDDS Dr.pdf
TDDS Dr.pdfTDDS Dr.pdf
TDDS Dr.pdf
 
Dietary Supplements, a Glance at Global Trends
Dietary Supplements, a Glance at Global TrendsDietary Supplements, a Glance at Global Trends
Dietary Supplements, a Glance at Global Trends
 
Key Stakeholders and the effect of their actions on the Financial Sustainabil...
Key Stakeholders and the effect of their actions on the Financial Sustainabil...Key Stakeholders and the effect of their actions on the Financial Sustainabil...
Key Stakeholders and the effect of their actions on the Financial Sustainabil...
 
Dry Powder Inhalers (DPIs) - At a glance
Dry Powder Inhalers (DPIs) -  At a glanceDry Powder Inhalers (DPIs) -  At a glance
Dry Powder Inhalers (DPIs) - At a glance
 
Mergers and Acquisitions in Indian Pharma Industry
Mergers and Acquisitions in Indian Pharma IndustryMergers and Acquisitions in Indian Pharma Industry
Mergers and Acquisitions in Indian Pharma Industry
 

More from Anup Soans

An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...Anup Soans
 
Key Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardKey Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardAnup Soans
 
Trends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingTrends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingAnup Soans
 
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thMedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thAnup Soans
 
Key Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMKey Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMAnup Soans
 
MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021Anup Soans
 
How can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsHow can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsAnup Soans
 
Why Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentWhy Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentAnup Soans
 
Digital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramDigital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramAnup Soans
 
Digital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramDigital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramAnup Soans
 
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsCOVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsAnup Soans
 
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
Architecture To Develop Pharma Business Leaders  For Today and Tomorrow  Architecture To Develop Pharma Business Leaders  For Today and Tomorrow
Architecture To Develop Pharma Business Leaders For Today and Tomorrow Anup Soans
 
What is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectWhat is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectAnup Soans
 
Digital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramDigital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramAnup Soans
 
Telemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsTelemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsAnup Soans
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalAnup Soans
 
Indian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollIndian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollAnup Soans
 
Healthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceHealthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceAnup Soans
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Anup Soans
 
MedicinMan December 2018 Issue
MedicinMan December 2018 IssueMedicinMan December 2018 Issue
MedicinMan December 2018 IssueAnup Soans
 

More from Anup Soans (20)

An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
 
Key Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardKey Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way Forward
 
Trends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingTrends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and Spending
 
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thMedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
 
Key Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMKey Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAM
 
MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021
 
How can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsHow can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand Patients
 
Why Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentWhy Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop Talent
 
Digital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramDigital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification Program
 
Digital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramDigital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification Program
 
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsCOVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
 
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
Architecture To Develop Pharma Business Leaders  For Today and Tomorrow  Architecture To Develop Pharma Business Leaders  For Today and Tomorrow
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
 
What is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectWhat is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research Project
 
Digital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramDigital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification Program
 
Telemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsTelemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian Doctors
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit Ghoshal
 
Indian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollIndian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View Poll
 
Healthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceHealthcare's Future will be Patient Experience
Healthcare's Future will be Patient Experience
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan
 
MedicinMan December 2018 Issue
MedicinMan December 2018 IssueMedicinMan December 2018 Issue
MedicinMan December 2018 Issue
 

Indian Pharma Market - Top 50 Ranking for Sep-2014

  • 1. Val  in  Crs MAT MTH Val  (Cr) MS% GR% Val  (Cr) MS% GR% CORPORATE 80565 100.00 9.1 7738 100.00 18.8 IPM 1 1 5030 6.24 5.8 467 6.03 16.7 Abbott  +  Abbott  HC  +  Novo 2 3 4343 5.39 15.0 378 4.89 8.9 Sun  Pharma 3 2 4038 5.01 10.3 427 5.51 38.4 Cipla 4 4 3480 4.32 8.0 312 4.03 12.0 Zydus  +  Biochem 5 7 2908 3.61 4.9 273 3.53 15.8 Ranbaxy 6 5 2899 3.60 10.2 305 3.95 30.9 Mankind 7 6 2887 3.58 13.8 290 3.75 19.1 Alkem  +  Cachet  +  Indchemie 8 8 2729 3.39 -­‐11.1 264 3.41 14.9 Glaxo 9 9 2710 3.36 12.8 259 3.35 19.7 Lupin 10 12 2348 2.91 6.3 229 2.96 23.9 Pfizer 11 10 2279 2.83 21.4 244 3.15 44.2 Macleods 12 14 2193 2.72 11.1 191 2.47 4.9 Emcure  +  Zuventus 13 13 2098 2.60 15.3 195 2.51 18.8 Intas 14 11 2023 2.51 19.9 230 2.98 39.7 Aristo 15 16 1984 2.46 -­‐0.5 180 2.32 13.2 Sanofi  India 16 18 1779 2.21 5.4 167 2.15 18.4 Torrent 17 15 1754 2.18 16.6 185 2.39 27.0 Glenmark 18 17 1719 2.13 9.4 167 2.15 17.5 Dr.  Reddys 19 20 1616 2.01 12.0 143 1.85 4.6 Micro  +  Bal 20 19 1470 1.82 24.7 152 1.96 22.1 Ipca 21 21 1466 1.82 10.0 128 1.66 7.6 USV 22 23 1145 1.42 -­‐1.0 105 1.36 13.4 Novartis 23 22 1103 1.37 12.8 117 1.51 30.6 Alembic 24 25 993 1.23 6.1 84 1.09 7.6 Wockhardt 25 24 843 1.05 6.8 90 1.16 24.0 FDC 26 26 815 1.01 10.7 77 0.99 13.0 Unichem 27 27 794 0.99 12.9 70 0.90 10.0 MSD  +  Fulford  +  Organon 28 29 687 0.85 16.0 60 0.78 9.6 Cadila 29 28 633 0.79 13.4 68 0.88 34.4 Indoco  Remedies 30 30 590 0.73 12.5 56 0.73 13.1 Franco 31 31 581 0.72 18.1 49 0.64 12.2 Eris 32 33 491 0.61 8.3 48 0.62 17.2 Himalaya 33 32 483 0.60 10.4 48 0.62 21.6 Merck 34 34 441 0.55 6.3 47 0.60 27.1 Blue  Cross 35 36 441 0.55 16.6 45 0.58 41.5 JB  Chemicals 36 38 398 0.49 -­‐6.4 43 0.55 49.9 Bharat  Serums 37 47 396 0.49 -­‐0.2 30 0.38 -­‐18.0 Astrazeneca 38 39 391 0.49 22.6 38 0.50 23.9 Meyer  Organics 39 40 385 0.48 2.4 37 0.48 12.8 Raptakos,  Brett 40 35 384 0.48 50.9 46 0.60 92.5 Akumentis 41 37 373 0.46 16.6 44 0.57 48.2 Hetero 42 43 372 0.46 9.8 35 0.45 12.1 Wallace  +  Indi  Pharma 43 42 353 0.44 16.1 36 0.47 26.9 Medley 44 46 342 0.42 10.8 31 0.40 18.8 Janssen 45 44 338 0.42 2.6 33 0.43 13.6 Win-­‐Medicare 46 45 332 0.41 10.7 32 0.41 14.4 Fourrts 47 49 315 0.39 38.4 28 0.37 35.9 Ajanta 48 48 310 0.39 41.7 29 0.38 22.1 Biocon With  Bonus  Units  at  Full  Value Rank MAT  Sep  -­‐14 Sep-­‐14
  • 2. 49 41 309 0.38 33.0 36 0.47 62.2 Apex  Lab 50 51 301 0.37 5.6 27 0.35 -­‐2.3 Albert  David
  • 3. MAT MTH Val  (Cr) MS% GR% Val  (Cr) MS% GR% 77530 100.00 9.2 7421 100.00 18.6 1 1 4934 6.36 5.8 457 6.15 16.9 2 3 4241 5.47 14.2 368 4.95 8.1 3 2 3799 4.90 12.6 399 5.38 38.7 4 4 3254 4.20 7.7 292 3.94 11.1 5 7 2799 3.61 5.2 262 3.53 15.8 9 6 2475 3.19 12.1 265 3.57 33.7 7 5 2692 3.47 14.5 270 3.64 20.0 6 8 2704 3.49 -­‐10.1 262 3.53 15.5 8 9 2654 3.42 13.0 254 3.42 20.3 10 11 2298 2.96 6.7 224 3.02 23.9 11 10 2135 2.75 21.2 226 3.05 43.9 12 14 2127 2.74 11.4 184 2.48 4.7 13 13 2070 2.67 15.6 192 2.59 19.0 15 12 1772 2.29 17.4 198 2.67 36.1 14 16 1944 2.51 -­‐0.7 175 2.36 12.5 16 17 1744 2.25 5.7 163 2.20 18.3 17 15 1701 2.19 16.2 179 2.41 26.4 18 18 1682 2.17 8.6 162 2.18 16.7 19 20 1546 1.99 12.5 136 1.83 4.1 21 19 1404 1.81 25.0 145 1.95 22.5 20 21 1460 1.88 10.1 128 1.72 7.8 22 23 1108 1.43 0.0 102 1.38 14.3 23 22 1072 1.38 13.5 114 1.53 31.3 24 25 974 1.26 6.2 83 1.11 7.4 25 24 819 1.06 6.7 87 1.18 24.0 26 26 797 1.03 10.3 75 1.01 12.8 27 27 783 1.01 12.6 68 0.92 9.5 28 29 665 0.86 16.1 58 0.78 9.2 29 28 593 0.76 13.4 63 0.85 33.7 31 30 569 0.73 11.9 54 0.73 12.6 30 31 578 0.74 17.9 49 0.66 12.4 32 32 489 0.63 8.0 48 0.64 17.0 33 33 471 0.61 9.4 46 0.63 21.1 35 36 405 0.52 7.1 42 0.57 26.5 34 35 424 0.55 16.7 43 0.59 42.4 37 37 391 0.50 -­‐6.8 42 0.57 49.5 36 47 392 0.51 -­‐0.6 29 0.40 -­‐17.7 39 39 379 0.49 22.4 37 0.50 23.4 38 40 379 0.49 2.2 37 0.50 12.9 40 34 377 0.49 52.4 46 0.61 94.0 43 38 339 0.44 16.7 40 0.54 46.7 41 43 353 0.46 17.4 34 0.46 22.3 44 42 335 0.43 16.4 34 0.46 26.8 42 45 341 0.44 10.8 31 0.42 18.8 45 44 333 0.43 1.2 33 0.44 13.1 46 46 316 0.41 9.7 30 0.40 12.8 47 49 313 0.40 38.2 28 0.38 35.8 48 48 310 0.40 41.7 29 0.39 22.1 Without  Bonus  Units Rank MAT  Sep  -­‐14 Sep-­‐14
  • 4. 49 41 300 0.39 33.1 35 0.48 64.3 50 51 295 0.38 5.4 27 0.36 -­‐2.8